AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15251161 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma concentrations of antioxidant micronutrients
Number of subjects: 48
Study 15251161 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced/oxidised vitamin C ratio
Number of subjects: 48
Study 11136647 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluoxetine
Number of subjects: 28
Study 11136647 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine monotherapy
Number of subjects: 28
Study 11136647 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 28
Study 10440302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mitomycin (1.4 mg/m2) and fluorouracil (166.7 mg/m2) twice weekly for 3 weeks after surgery, and oral UFT (uracil plus tegafur, 300 mg daily) for 18 months
Number of subjects: 579
Study 10440302 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 579
Study 7759461 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 million U/m2 rIFN‐alpha 2a (n = 4)
Number of subjects: 7
Study 7759461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 7
Study 2319018 — intervention group
Group type: EXPERIMENTAL
Intervention: econazole nitrate (Spectazole)
Number of subjects: 24
Study 2319018 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 24
Study 6108445 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Number of subjects: 191
Study 6108445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 191
Study 6108445 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine and immunoglobulin
Number of subjects: 191
Study 6108445 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 191
Study 6108445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas infection of burns
Number of subjects: 191
Study 30456502 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted right colectomy (RAC)
Number of subjects: 71
Study 30456502 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic-assisted right colectomy (LAC)
Number of subjects: 71
Study 28575646 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) active-treatment group
Number of subjects: 48
Study 28575646 — intervention group
Group type: COMPARATOR
Intervention: Medication-only control group
Number of subjects: 48
Study 24450301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day for 12 weeks
Number of subjects: 220
Study 24450301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 23903032 — intervention group
Group type: EXPERIMENTAL
Intervention: Zembrin (25 mg)
Number of subjects: 16
Study 23903032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21780946 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 7392
Study 21780946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7392
Study 19300221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 0
Study 17702958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of urokinase (UK)
Number of subjects: 114
Study 17702958 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 14671730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical drug trial consent process
Number of subjects: 60
Study 14671730 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional capacity measurement
Number of subjects: 60
Study 14671730 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for participation in research
Number of subjects: 60
Study 14671730 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning
Number of subjects: 60
Study 14671730 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric symptoms
Number of subjects: 60
Study 11464260 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/benazepril 10 mg
Number of subjects: 454
Study 11464260 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 454
Study 11464260 — intervention group
Group type: COMPARATOR
Intervention: Benazepril 10 mg
Number of subjects: 454
Study 11464260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 11416702 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in alcohol intake (1 drink per day for women, 2 drinks per day for men)
Number of subjects: 0
Study 11416702 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular alcohol consumption
Number of subjects: 0
Study 11416702 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive alcohol intake
Number of subjects: 0
Study 9234577 — intervention group
Group type: EXPERIMENTAL
Intervention: VICOP-B (idarubicin 8 mg/sqm)
Number of subjects: 104
Study 9234577 — intervention group
Group type: EXPERIMENTAL
Intervention: VICOP-B (idarubicin 10 mg/sqm)
Number of subjects: 104
Study 9234577 — intervention group
Group type: COMPARATOR
Intervention: VACOP-B (doxorubicin 50 mg/sqm)
Number of subjects: 104
Study 9234577 — intervention group
Group type: EXPERIMENTAL
Intervention: VICOP-B (idarubicin)
Number of subjects: 104
Study 9234577 — intervention group
Group type: COMPARATOR
Intervention: VACOP-B (doxorubicin)
Number of subjects: 104
Study 8480832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant buspirone
Number of subjects: 13
Study 8480832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3607808 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 8
Study 3607808 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine + Isosorbide 5‐mononitrate
Number of subjects: 8
Study 3607808 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 8
Study 2125869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acupuncture and medication (ear needling and body needling with half-dosage Innovar and 0.1% lidocaine for scalp infiltration)
Number of subjects: 174
Study 2125869 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus 0.1% lidocaine
Number of subjects: 174
Study 2125869 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture plus normal saline
Number of subjects: 174
Study 2125869 — intervention group
Group type: COMPARATOR
Intervention: 0.1% lidocaine alone
Number of subjects: 174
Study 1099171 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 0
Study 1099171 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 1099171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31721112 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural corticosteroids, cerebrospinal fluid drainage, controlled vascular hypertension
Number of subjects: 50
Study 31090748 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal hexagon implants (IHC)
Number of subjects: 20
Study 31090748 — intervention group
Group type: COMPARATOR
Intervention: External hexagon implants (EHC)
Number of subjects: 20
Study 31090748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IHC and EHC
Number of subjects: 20
Study 27464593 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg every 6 hours)
Number of subjects: 198
Study 27464593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 26932695 — intervention group
Group type: EXPERIMENTAL
Intervention: EECP therapy
Number of subjects: 99
Study 26932695 — intervention group
Group type: COMPARATOR
Intervention: Sham EECP therapy
Number of subjects: 99
Study 24573688 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos/software/internet
Number of subjects: 240
Study 24573688 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized streetside instruction
Number of subjects: 240
Study 24573688 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)
Number of subjects: 240
Study 24573688 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 240
Study 22463698 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum chromium-based everolimus-eluting stent (PtCr-EES)
Number of subjects: 3750
Study 22463698 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chromium-based zotarolimus-eluting stent (CoCr-ZES)
Number of subjects: 3750
Study 22463698 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet antiplatelet therapy (TAT)
Number of subjects: 3750
Study 22463698 — intervention group
Group type: COMPARATOR
Intervention: Double-dose antiplatelet therapy (DDAT)
Number of subjects: 3750
Study 19116965 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential monotherapy
Number of subjects: 508
Study 19116965 — intervention group
Group type: EXPERIMENTAL
Intervention: step-up combination therapy starting with methotrexate
Number of subjects: 508
Study 19116965 — intervention group
Group type: EXPERIMENTAL
Intervention: initial combination therapy including tapered high-dose prednisone
Number of subjects: 508
Study 19116965 — intervention group
Group type: EXPERIMENTAL
Intervention: initial combination therapy with methotrexate and infliximab
Number of subjects: 508
Study 18158044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure spray of 0.3 mL 2% lidocaine using the MadaJet Medical Injector
Number of subjects: 50
Study 18158044 — intervention group
Group type: COMPARATOR
Intervention: Traditional vasal block with three 1.7-mL ampules of mepivacaine using a 27-gauge needle
Number of subjects: 50
Study 15193965 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy group (short-term psychodynamic therapy)
Number of subjects: 108
Study 15193965 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized glucocorticoid therapy)
Number of subjects: 108
Study 15193965 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy group
Number of subjects: 108
Study 15193965 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 11779284 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine cotherapy (5-20 mg/d)
Number of subjects: 344
Study 11779284 — intervention group
Group type: COMPARATOR
Intervention: Placebo + mood-stabilizer (valproate or lithium)
Number of subjects: 344
Study 9807607 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.0 mg/kg
Number of subjects: 80
Study 9807607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg/kg
Number of subjects: 80
Study 9807607 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 0.5 mg/kg
Number of subjects: 80
Study 9807607 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 0.25 mg/kg
Number of subjects: 80
Study 9807607 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 0.5 mg/kg or more
Number of subjects: 80
Study 7621645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg daily for 2 days)
Number of subjects: 4
Study 7621645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine sulphate (40 mg daily for 2 days)
Number of subjects: 4
Study 7621645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + Ephedrine
Number of subjects: 4
Study 7621645 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study 2488093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone infusion (10-20 mg/kg in saline infusion within 4 to 10 hours through a central vein)
Number of subjects: 319
Study 2488093 — intervention group
Group type: COMPARATOR
Intervention: Glucose-insulin-potassium (GIK) infusion (150-300 g of glucose, 25-50 IU of insulin, and 80-120 mEq of KCl in 1000 cc of water at a rate of 1.5-2.0 ml/g/hour)
Number of subjects: 319
Study 320630 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen-Sodium (NS) 1100 mg
Number of subjects: 10
Study 30414606 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch Surgery (TS) app
Number of subjects: 12
Study 30414606 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper-based learning program
Number of subjects: 12
Study 28012682 — intervention group
Group type: EXPERIMENTAL
Intervention: AD risk assessments with genotype results
Number of subjects: 79
Study 28012682 — intervention group
Group type: COMPARATOR
Intervention: AD risk assessments without genotype results
Number of subjects: 79
Study 28012682 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of ε4 positive results
Number of subjects: 79
Study 28012682 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of ε4 negative results
Number of subjects: 79
Study 25830924 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS to the right secondary somatosensory cortex (S2)
Number of subjects: 16
Study 25830924 — intervention group
Group type: COMPARATOR
Intervention: High-frequency rTMS to the sensorimotor cortex (S1/M1)
Number of subjects: 16
Study 25830924 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 23301731 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐IUS
Number of subjects: 571
Study 23301731 — intervention group
Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 571
Study 21829566 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole‐cell and killed whole‐cell‐only oral cholera vaccines
Number of subjects: 0
Study 21829566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19588485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline insulin levels (highest tertile)
Number of subjects: 5450
Study 19588485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glucose levels
Number of subjects: 5450
Study 19588485 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements of serum insulin
Number of subjects: 5450
Study 17349075 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood orange juice (BOJ, 300 ml providing 150 mg vitamin C)
Number of subjects: 7
Study 17349075 — intervention group
Group type: COMPARATOR
Intervention: C-drink (same amount of vitamin C)
Number of subjects: 7
Study 17349075 — intervention group
Group type: COMPARATOR
Intervention: S-drink (sugars)
Number of subjects: 7
Study 15065959 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-risk-reduction intervention
Number of subjects: 408
Study 15065959 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use reduction (SUR) intervention
Number of subjects: 408
Study 15065959 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 408
Study 11587503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release (SR) paracetamol (Panadol Extend)
Number of subjects: 627
Study 11587503 — intervention group
Group type: COMPARATOR
Intervention: Immediate release (IR) paracetamol (Panadol)
Number of subjects: 627
Study 9848528 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE membrane
Number of subjects: 8
Study 9848528 — intervention group
Group type: EXPERIMENTAL
Intervention: polylactic acid membrane
Number of subjects: 8
Study 9848528 — intervention group
Group type: EXPERIMENTAL
Intervention: polyglactin 910 membrane
Number of subjects: 8
Study 9848528 — intervention group
Group type: COMPARATOR
Intervention: All membranes
Number of subjects: 8
Study 8124836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 331
Study 8124836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 2531605 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg)
Number of subjects: 10
Study 1094945 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride
Number of subjects: 0
Study 1094945 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 0
Study 31697242 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alcohol screening and brief intervention via email
Number of subjects: 0
Study 30261963 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 128
Study 30261963 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 128
Study 27802250 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 50
Study 27802250 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 50
Study 27802250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study 24465671 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily repetitive training using the rubber hand illusion paradigm
Number of subjects: 0
Study 24465671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep after training
Number of subjects: 0
Study 24465671 — intervention group
Group type: EXPERIMENTAL
Intervention: Wakefulness after training
Number of subjects: 0
Study 22179931 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 600 mg
Number of subjects: 136
Study 22179931 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine HCl 200 mg
Number of subjects: 136
Study 19334061 — intervention group
Group type: COMPARATOR
Intervention: MRI treatment effects
Number of subjects: 6591
Study 19334061 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 6591
Study 17229229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg (group K)
Number of subjects: 160
Study 17229229 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg (group G)
Number of subjects: 160
Study 17229229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg + Granisetron 1.5 mg (group KG)
Number of subjects: 160
Study 17229229 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, group P)
Number of subjects: 160
Study 14991494 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with three or more adenomas with at least one located on the proximal colon
Number of subjects: 552
Study 14991494 — intervention group
Group type: COMPARATOR
Intervention: Patients with one or two adenomas on the distal colon
Number of subjects: 552
Study 11665964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisolone, methotrexate, and sulfasalazine)
Number of subjects: 155
Study 11665964 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 155
Study 11665964 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline damage, swelling, or pain in a joint
Number of subjects: 155
Study 11665964 — intervention group
Group type: EXPERIMENTAL
Intervention: Swelling score (range 0‐2)
Number of subjects: 155
Study 11665964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp scale (range 0‐8 per joint)
Number of subjects: 155
Study 11665964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scale (range 0‐3)
Number of subjects: 155
Study 11665964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pain and swelling scores over the year
Number of subjects: 155
Study 9680497 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt intake (220 mmol/day)
Number of subjects: 18
Study 9680497 — intervention group
Group type: COMPARATOR
Intervention: Low salt intake (40 mmol/day)
Number of subjects: 18
Study 7863948 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging with primary criteria of cortical breakdown, replacement of bone marrow fat, or gadopentetate dimeglumine enhancement
Number of subjects: 22
Study 7863948 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 22
Study 7863948 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative MR study
Number of subjects: 22
Study 7863948 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive MR study
Number of subjects: 22
Study 7863948 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium enhancement
Number of subjects: 22
Study 2573147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms b.i.d.
Number of subjects: 0
Study 2573147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 100 micrograms b.i.d. (in rats)
Number of subjects: 0
Study 2573147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1201644 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous penta-gastrin
Number of subjects: 14
Study 1201644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin
Number of subjects: 14
Study 1201644 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 14
Study 30657406 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 302
Study 30657406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine group
Number of subjects: 302
Study 30657406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine/Other Stimulant group
Number of subjects: 302
Study 30657406 — intervention group
Group type: EXPERIMENTAL
Intervention: Other Stimulant group (primarily methamphetamine)
Number of subjects: 302
Study 30657406 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall construct validity
Number of subjects: 302
Study 28781111 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial biopsy prediction model
Number of subjects: 7963
Study 28781111 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat biopsy prediction model
Number of subjects: 7963
Study 25638351 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth PTSD program, motivational interviewing-based smoking cessation curricula via telehealth device, weekly motivational interviewing counseling phone calls
Number of subjects: 120
Study 25638351 — intervention group
Group type: COMPARATOR
Intervention: Usual care including a telehealth PTSD program with a device that delivered PTSD information and in-home care management
Number of subjects: 120
Study 25638351 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 120
Study 22981045 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) plus conventional sepsis treatment
Number of subjects: 12
Study 22981045 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional sepsis treatment only)
Number of subjects: 12
Study 21306237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib at a dose of 37.5 mg per day
Number of subjects: 171
Study 21306237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 18164937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 573